Protective Action of Methylprednisolone on the Myocardium during Experimental Myocardial Ischemia in the Cat

¹ Department of Physiology, University of Virginia School of Medicine, Charlottesville, Virginia 22901

Cats subjected to coronary artery occlusion were used to study the effect of methylprednisolone on the release of lysosomal acid hydrolases and creatine phosphokinase (CPK) from ischemic myocardial tissue. Plasma CPK activity was increased significantly 2 hours after occlusion and increased eightfold 5 hours after ligation in vehicle-treated cats. Intravenous administration of methylprednisolone (30 mg/kg) 30 minutes before or 60 minutes after occlusion significantly limited the increases in plasma CPK activity to values only slightly greater than those observed in sham-operated cats. Plasma activities of the lysosomal hydrolases, -glucuronidase and cathepsin D, were comparable in all groups of cats and did not change during the 5-hour observation period. Nevertheless, cathepsin D and -glucuronidase activities were reduced 41% and 33%, respectively, in the ischemic portion of the myocardium of untreated cats subjected to coronary artery ligation. The CPK activity of the ischemic myocardium was reduced 43% in these cats. Pre- or posttreatment of cats with methylprednisolone prevented the decline in CPK and lysosomal hydrolase activity of ischemic myocardium. These data indicate that lysosomal disruption is a consequence of myocardial ischemia and that pre- or posttreatment with methylprednisolone prevents the leakage of myocardial lysosomal and cellular enzymes. Moreover, the methylprednisolone-induced stabilization of myocardial membranes appears to be related to the ability of glucocorticoid to limit infarct size following myocardial ischemia.

Submitted on October 15, 1973
Accepted on April 1, 1974

This article has been cited by other articles:

				A. S. Mihailidou, T. Y. Loan Le, M. Mardini, and J. W. Funder Glucocorticoids Activate Cardiac Mineralocorticoid Receptors During Experimental Myocardial Infarction Hypertension, December 1, 2009; 54(6): 1306 - 1312. [Abstract] [Full Text] [PDF]

				H. Sun, E. Sheveleva, B. Xu, H. Inoue, T. G. Bowden, and Q. M. Chen Corticosteroids induce COX-2 expression in cardiomyocytes: role of glucocorticoid receptor and C/EBP-{beta} Am J Physiol Cell Physiol, October 1, 2008; 295(4): C915 - C922. [Abstract] [Full Text] [PDF]

				Q. M. Chen, D. Alexander, H. Sun, L. Xie, Y. Lin, J. Terrand, S. Morrissy, and S. Purdom Corticosteroids Inhibit Cell Death Induced by Doxorubicin in Cardiomyocytes: Induction of Antiapoptosis, Antioxidant, and Detoxification Genes Mol. Pharmacol., June 1, 2005; 67(6): 1861 - 1873. [Abstract] [Full Text] [PDF]

				M K C Ng and D S Celermajer Glucocorticoid treatment and cardiovascular disease Heart, August 1, 2004; 90(8): 829 - 830. [Abstract] [Full Text] [PDF]

				A. Skyschally, M. Haude, H. Dorge, M. Thielmann, A. Duschin, A. van de Sand, I. Konietzka, A. Buchert, S. Aker, P. Massoudy, et al. Glucocorticoid Treatment Prevents Progressive Myocardial Dysfunction Resulting From Experimental Coronary Microembolization Circulation, May 18, 2004; 109(19): 2337 - 2342. [Abstract] [Full Text] [PDF]

				H. W.M Niessen, P. A.J Krijnen, C. A Visser, C. J.L.M Meijer, and C Erik Hack Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res, October 15, 2003; 60(1): 68 - 77. [Abstract] [Full Text] [PDF]

				M. A. Chaney Corticosteroids and Cardiopulmonary Bypass : A Review of Clinical Investigations Chest, March 1, 2002; 121(3): 921 - 931. [Abstract] [Full Text] [PDF]

				T. Tamaki, S. Uchiyama, Y. Uchiyama, A. Akatsuka, R. R. Roy, and V. R. Edgerton Anabolic steroids increase exercise tolerance Am J Physiol Endocrinol Metab, June 1, 2001; 280(6): E973 - E981. [Abstract] [Full Text] [PDF]

				R. Pabla, A. J. Buda, D. M. Flynn, S. A. Blesse, A. M. Shin, M. J. Curtis, and D. J. Lefer Nitric Oxide Attenuates Neutrophil-Mediated Myocardial Contractile Dysfunction After Ischemia and Reperfusion Circ. Res., January 1, 1996; 78(1): 65 - 72. [Abstract] [Full Text]

				H. Kawabata, K. Takada, and R. Katori Effect of Methylprednisolone on Metabolism and Contractility in the Stunned Myocardium Angiology, October 1, 1995; 46(10): 895 - 904. [Abstract] [PDF]

				S. DeSilva, D. B. Drachman, D. Mellits, and R. W. Kuncl Prednisone Treatment in Duchenne Muscular Dystrophy: Long-term Benefit Arch Neurol, August 1, 1987; 44(8): 818 - 822. [Abstract] [PDF]

				R. E. RUDE, J. E. MULLER, and B. EUGENE Efforts to Limit the Size of Myocardial Infarcts Ann Intern Med, December 1, 1981; 95(6): 736 - 761. [Abstract] [PDF]

				F. A. Cecena-Seldner and J. Villarreal Effect of the Kallikrein Inhibitor Aprotinin on Myocardial Ischemia and Necrosis in Man Angiology, July 1, 1980; 31(7): 488 - 496. [Abstract] [PDF]

				A. Lefer, M. Ogletree, J. Smith, M. Silver, K. Nicolaou, W. Barnette, and G. Gasic Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia Science, April 7, 1978; 200(4337): 52 - 54. [Abstract] [PDF]

				V. Caride and B. Zaret Liposome accumulation in regions of experimental myocardial infarction Science, November 18, 1977; 198(4318): 735 - 738. [Abstract] [PDF]

				S. Raju, W. J. Gibson, B. Heath, V. Lockhart, and H. Conn Experimental Evaluation of Coronary Infusates in Dogs Arch Surg, November 1, 1975; 110(11): 1374 - 1382. [Abstract] [PDF]